Brought to you by 
BioMarin pays $691mm in cash plus up to $160mm in earn-outs for Prosensa
26 Aug 2020
Executive Summary
BioMarin Pharmaceutical Inc. is acquiring all the outstanding shares of Dutch biotech Prosensa Holding NV for $17.75 each (a 53% premium), valuing the transaction at $641mm. At closing, BioMarin will buy $50mm in Prosensa convertible debt; if the transaction fails, the note will convert into 4.4mm Prosensa shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMarin pays $691mm in cash plus up to $160mm in earn-outs for Prosensa
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice